Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialDaniel P. Petrylak, Cristiano Ferrario, Daniel Castellano et al.|The Lancet|2017Cited by 177
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialDaniel P. Petrylak, Siobhan Ng, Ronald de Wit et al.|The Lancet Oncology|2019Cited by 87
Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasmsJ. G. Berdeja, Aaron T. Gerds, Francesca Palandri et al.|Leukemia Research|2018Cited by 50